Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The latest in early phase trials, including bispecific antibodies for IO, radiotheranostics, MAPkinase and associated targets (KRAS G12C, MAP2K4, combos) and more, will be presented in this multi-stakeholder forum
Staying updated with the latest advancements in cancer care has never been easier. Mark your calendar for the upcoming Deep Dive webinar on Lung Cancer (5 Feb)
Join experts to explore cutting-edge insights into sarcoma and rare cancers: multidisciplinary care, molecular diagnostics, precision therapies, and research advancements to improve patient outcomes
Is your ESMO Library up to date? We published three new titles last year: Breast Cancer, Gynaecological Tumours and Lymphomas - all written with young oncologists in mind
Join us in Vienna, or online, for a comprehensive exploration of the latest clinical and research developments in gynaecological malignancies
Designed to educate and train early-career investigators in the best practices of clinical trial design & provide access to experienced clinical investigators
Both the Oncogene-Addicted and Non-Oncogene-Addicted ESMO Living Guideline on Metastatic NSCLC are updated - browse them now
Online application is now open until 18 February 2025
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
New indication concerns monotherapy as part of consolidation therapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-negative CD19-positive B-cell precursor ALL
Findings from the SGNTUC-019 study
Findings from a translational analysis of the FOENIX study and a comprehensive analysis of primary data from a multi-institutional patient cohort with FGFR-altered cholangiocarcinoma
Updated results from the KEYNOTE-756 trial show benefits of the chemoimmunotherapy across subgroups of patients with ER+/HER2− breast cancer
Strengthening Collaboration to Advance Europe’s Beating Cancer Plan
Findings from the TROPION-Lung05 study
Evidence for efficacy is based on the results from the BREAKWATER study
Change concerns the first-line treatment of patients with endometrial cancer
The reduced efficacy compared to the first-line standard of care led to the termination of the SKYSCRAPER-06 study
New indication concerns monotherapy as part of consolidation therapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-negative CD19-positive B-cell precursor ALL
Findings from the SGNTUC-019 study
Findings from a translational analysis of the FOENIX study and a comprehensive analysis of primary data from a multi-institutional patient cohort with FGFR-altered cholangiocarcinoma
Findings from the TROPION-Lung05 study
Evidence for efficacy is based on the results from the BREAKWATER study
Change concerns the first-line treatment of patients with endometrial cancer
Findings from the KATHERINE study
Findings from a substudy 02C of the KEYMAKER-U02 trial
Findings from the RedirecTT-1 study
The ESMO Immuno-Oncology Congress 2024 will take place in Geneva, Switzerland, from December 11-13, with an option to attend virtually. Leading experts will present and discuss the research advancements in the rapidly evolving field of immuno-oncology
The ESMO Asia Congress 2024 is the annual event dedicated to multidisciplinary oncology in the Asian region
The Molecular Analysis for Precision Oncology Congress 2024 (MAP) is the appointment where globally recognised experts will present and discuss research in precision medicine, technologies for cancer profiling, mechanisms driving tumour expansion, metastatic dissemination, clonal evolution, and biomarker-driven development of targeted therapeutics
Immunotherapy, which works by enabling the body’s immune system to recognise and destroy cancer cells improves long-term overall survival in patients with advanced melanoma in results from large international studies reported at ESMO 2024
Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found ‘promising’ antitumour activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers
The ESMO Congress 2024 taking place 13-17 September in Barcelona, Spain, offers a comprehensive view of the current drug development landscape, with existing medicines demonstrating benefit in additional applications and new agents emerging in large numbers as the range of potential molecular targets for therapy continues to expand
The ESMO Congress 2024 will hold a press conference to introduce and discuss the “Eyes to the Future” Presidential Symposium 3, that will be presenting prominent approaches that have the potential to become increasingly effective and influential components of cancer treatment in the (near) future.
The European Society for Medical Oncology (ESMO) is calling on all actors of the oncology community to commit to improving the well-being of the cancer workforce and join in 11 actions outlined in a paper published today in ESMO Open
According to two international studies presented at the ESMO Congress 2024, women who breastfeed after receiving treatment for breast cancer, including those with a germline BRCA mutation (an inherited change in BRCA genes that significantly increases the risk of developing certain cancers, especially breast cancer), do not face an increased risk of recurrence or developing new breast cancers
ESMO welcomes the outcome of the hearings for Olivér Várhelyi, Commissioner-designate for Health and Animal Welfare, where several topics relevant for the oncology community were addressed in a positive or at least promising way
The ESMO Award for Immuno-Oncology 2024 is presented to Ton N. Schumacher in recognition of his exceptional contributions to cancer immunology and to our understanding of the mechanism of how immunotherapy works
Bringing another annual reunion of the global oncology community to a resounding close, the 34,000 attendees of the ESMO Congress 2024 had the opportunity to gather around to listen to the most important results presented in different tumour types and research areas
ESMO is pleased to announce the 2024 ESMO Fellowship awardees
The ESMO Precision Medicine Working Group (PMWG) together with a multidisciplinary team of international experts, have developed the ESMO Tumour-Agnostic Classifier and Screener (ETAC-S)
The recipients of the 2024 ESMO Society Awards have been announced today by ESMO
Hundreds of trials are being delayed in Europe due to unintended consequences of the IVDR posing an existential threat to Europe’s role as a leader in global oncological research
The Impact Factor (IF) of ESMO journals has remained strong this year, according to the 2024 Journal Citation Reports published by Clarivate Analytics
ESMO has announced today the results of its Presidential elections following the closure of the voting system on Monday, 10 June 2024.
Updated results from the KEYNOTE-756 trial show benefits of the chemoimmunotherapy across subgroups of patients with ER+/HER2− breast cancer
The reduced efficacy compared to the first-line standard of care led to the termination of the SKYSCRAPER-06 study
Early-phase data suggest that intratumour injections of ORCA-010 may convert cold tumours into immunogenic ones
Effectiveness, applicability and accessibility measure the value of novel technologies and therapies in oncology
Recent findings consolidate the role of liquid biopsy in the field, but prospective research is needed
Despite being active in this disease setting, the antibody-drug conjugate was associated to high rates of neutropenic complications
Different combinations of immunotherapy agent and radiotherapy or chemoradiotherapy were tested in some patient populations in two studies
Next steps for research include personalising regimens and learning how to predict response and toxicity
Studies explore the prognostic and predictive values of circulating DNA tumour fraction and single-cell RNA sequencing of peripheral blood mononuclear cells
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
South Africa
South Africa
Switzerland
France
United Kingdom
Switzerland
France
Switzerland
Peru
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Examination 2025 will be held on Saturday 18 October during the ESMO Congress 2025.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
